RECORDATI |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 48.1 EUR | -1.39% |
|
-2.32% | -1.49% |
| Jun. 12 | Stock markets in the green; BPER Bank leads the rises | AN |
| Jun. 11 | Recordati buys back more than 50,000 of its own ordinary shares | AN |
| Sales 2024 * | 2.3B 2.46B | Sales 2025 * | 2.44B 2.61B | Capitalization | 9.89B 10.58B |
|---|---|---|---|---|---|
| Net income 2024 * | 474M 507M | Net income 2025 * | 522M 559M | EV / Sales 2024 * | 4.85 x |
| Net Debt 2024 * | 1.26B 1.34B | Net Debt 2025 * | 1.01B 1.08B | EV / Sales 2025 * | 4.47 x |
| P/E ratio 2024 * |
21.6
x | P/E ratio 2025 * |
19.3
x | Employees | 4,455 |
| Yield 2024 * |
2.93% | Yield 2025 * |
3.22% | Free-Float | 46.83% |
More Fundamentals
* Assessed data
More news
Latest transcript on Recordati
More press releases
More news
| 1 day | -1.39% | ||
| 1 week | -2.32% | ||
| Current month | -0.62% | ||
| 1 month | -4.75% | ||
| 3 months | -9.00% | ||
| 6 months | +2.32% | ||
| Current year | -1.49% |
1 week
47.92
49.82
1 month
47.2852.35
Current year
47.2853.40
1 year
41.7553.40
3 years
34.5257.90
5 years
28.2657.90
10 years
11.3057.90
| Managers | Title | Age | Since |
|---|---|---|---|
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Luigi la Corte
DFI | Director of Finance/CFO | 54 | 19-10-31 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Cathrin Petty
BRD | Director/Board Member | 51 | 18-06-11 |
Robert Koremans
CEO | Chief Executive Officer | 61 | 21-11-30 |
Andrea Recordati
CHM | Chairman | 52 | 98-04-28 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 1.52% | 5 M€ | +12.55% |
| Date | Price | Change | Volume |
|---|---|---|---|
| 24-06-14 | 48.1 | -1.39% | 176,148 |
| 24-06-13 | 48.78 | -0.97% | 156,329 |
| 24-06-12 | 49.26 | +1.73% | 109,634 |
| 24-06-11 | 48.42 | -2.26% | 181,292 |
| 24-06-10 | 49.54 | -0.32% | 177,477 |
Real-time Borsa Italiana, June 14, 2024 at 11:44 am EDT
More quotes
Recordati S.p.A. specializes in the research, development, production and marketing of pharmaceutical products. Net sales break down by family of products as follows:
- pharmaceutical and OTC products (67.9%): for the treatment of viral infections, cardiovascular, dermatological, gynecological diseases, etc.;
- medicines for rare diseases (32.1%).
Net sales are distributed geographically as follows: Italy (15%), Europe (58.5%), America (17.5%), Australasia (6.2%) and Africa (2.8%).
Sector
Pharmaceuticals
Calendar
2024-06-18
- Mediobanca Italian CEO Conference
Related indices
Trading Rating
Investor Rating
ESG Refinitiv
A-
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
10
Last Close Price
48.1
EUR
Average target price
52.64
EUR
Spread / Average Target
+9.44%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -1.49% | 10.79B | |
| +50.70% | 795B | |
| +41.96% | 627B | |
| -7.15% | 350B | |
| +18.77% | 328B | |
| +8.79% | 294B | |
| +18.02% | 245B | |
| +1.27% | 222B | |
| +11.95% | 215B | |
| +3.68% | 160B |
- Stock Market
- Equities
- REC Stock
